Matches in SemOpenAlex for { <https://semopenalex.org/work/W2957799212> ?p ?o ?g. }
- W2957799212 endingPage "10" @default.
- W2957799212 startingPage "1" @default.
- W2957799212 abstract "PURPOSE To understand the quality of life (QoL) for patients with neuroendocrine tumors (NETs) through comparison of QoL questionnaires and symptom tracking as well as journaling via the Carcinoid NETs Health Storylines mobile application (app). PATIENTS AND METHODS This was a 12-week prospective, observational study of US patients with NET who were taking long-acting somatostatin analogs. National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) and European Organisation for Research and Treatment of Cancer (EORTC) questionnaires were administered three times. Patients also monitored symptoms, mood, bowel movements, food, activity, and sleep, and they journaled in their app, which was coded by theme and sentiment for qualitative analysis. RESULTS Of the 120 patients with NET, 78% were women (mean age, 57 years); 76% had gastroenteropancreatic NETs, and 88% had metastases. Lanreotide depot and octreotide long-acting release (LAR) were used by 41% and 59%, respectively. The most common symptoms at baseline were fatigue (76.7%), diarrhea (62.5%), abdominal discomfort (64.1%), and trouble sleeping (57.5%). The majority completed five of six survey assessments (median, 5; mean, 5.1) and tracked four symptoms in the app (median, 4; mean, 5.5); the average frequency was 41.6 days for each symptom (median, 43; mean, 41.6; range, 1 to 84 days [12 weeks]). Without treatment change, most EORTC-assessed physical symptoms decreased from baseline to midpoint (eg, 59.3% at baseline v 33% at midpoint reported “quite a bit” or “very much” diarrhea; P = .002). App-based symptom tracking revealed large day-to-day variation, but weekly averages correlated well with survey scores. Journal entries showed that more patients made predominantly negative unsolicited entries about their injection experience with octreotide LAR compared with lanreotide (13 of 17 v two of 13; P < .001). CONCLUSION Patients with NET experience a large symptom burden that varies daily. A decrease in physical symptoms on QoL surveys suggests an effect from daily app-based monitoring or journaling, which may reduce recall bias and benefit the patient’s experience of symptoms." @default.
- W2957799212 created "2019-07-23" @default.
- W2957799212 creator A5011261788 @default.
- W2957799212 creator A5016574266 @default.
- W2957799212 creator A5027600192 @default.
- W2957799212 creator A5029879251 @default.
- W2957799212 creator A5033706484 @default.
- W2957799212 date "2019-12-01" @default.
- W2957799212 modified "2023-09-30" @default.
- W2957799212 title "Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application" @default.
- W2957799212 cites W1549369569 @default.
- W2957799212 cites W1982811083 @default.
- W2957799212 cites W2014454803 @default.
- W2957799212 cites W2048511630 @default.
- W2957799212 cites W2048997600 @default.
- W2957799212 cites W2073935722 @default.
- W2957799212 cites W2075083707 @default.
- W2957799212 cites W2078677780 @default.
- W2957799212 cites W2103271284 @default.
- W2957799212 cites W2104799602 @default.
- W2957799212 cites W2117876486 @default.
- W2957799212 cites W2120434059 @default.
- W2957799212 cites W2126720544 @default.
- W2957799212 cites W2135049144 @default.
- W2957799212 cites W2170056569 @default.
- W2957799212 cites W2171228644 @default.
- W2957799212 cites W2286852446 @default.
- W2957799212 cites W2313482334 @default.
- W2957799212 cites W2317210650 @default.
- W2957799212 cites W2324095211 @default.
- W2957799212 cites W2418960531 @default.
- W2957799212 cites W2510845368 @default.
- W2957799212 cites W2560239468 @default.
- W2957799212 cites W2590625439 @default.
- W2957799212 cites W2607021911 @default.
- W2957799212 cites W2608160487 @default.
- W2957799212 cites W2626155315 @default.
- W2957799212 cites W2787318350 @default.
- W2957799212 doi "https://doi.org/10.1200/cci.19.00025" @default.
- W2957799212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6873920" @default.
- W2957799212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31283354" @default.
- W2957799212 hasPublicationYear "2019" @default.
- W2957799212 type Work @default.
- W2957799212 sameAs 2957799212 @default.
- W2957799212 citedByCount "11" @default.
- W2957799212 countsByYear W29577992122020 @default.
- W2957799212 countsByYear W29577992122021 @default.
- W2957799212 countsByYear W29577992122022 @default.
- W2957799212 countsByYear W29577992122023 @default.
- W2957799212 crossrefType "journal-article" @default.
- W2957799212 hasAuthorship W2957799212A5011261788 @default.
- W2957799212 hasAuthorship W2957799212A5016574266 @default.
- W2957799212 hasAuthorship W2957799212A5027600192 @default.
- W2957799212 hasAuthorship W2957799212A5029879251 @default.
- W2957799212 hasAuthorship W2957799212A5033706484 @default.
- W2957799212 hasBestOaLocation W29577992121 @default.
- W2957799212 hasConcept C118552586 @default.
- W2957799212 hasConcept C126322002 @default.
- W2957799212 hasConcept C159110408 @default.
- W2957799212 hasConcept C1862650 @default.
- W2957799212 hasConcept C2776297358 @default.
- W2957799212 hasConcept C2777433750 @default.
- W2957799212 hasConcept C2779066768 @default.
- W2957799212 hasConcept C2779609023 @default.
- W2957799212 hasConcept C2779802037 @default.
- W2957799212 hasConcept C2779951463 @default.
- W2957799212 hasConcept C2780733359 @default.
- W2957799212 hasConcept C2781025020 @default.
- W2957799212 hasConcept C2984496839 @default.
- W2957799212 hasConcept C71315377 @default.
- W2957799212 hasConcept C71924100 @default.
- W2957799212 hasConceptScore W2957799212C118552586 @default.
- W2957799212 hasConceptScore W2957799212C126322002 @default.
- W2957799212 hasConceptScore W2957799212C159110408 @default.
- W2957799212 hasConceptScore W2957799212C1862650 @default.
- W2957799212 hasConceptScore W2957799212C2776297358 @default.
- W2957799212 hasConceptScore W2957799212C2777433750 @default.
- W2957799212 hasConceptScore W2957799212C2779066768 @default.
- W2957799212 hasConceptScore W2957799212C2779609023 @default.
- W2957799212 hasConceptScore W2957799212C2779802037 @default.
- W2957799212 hasConceptScore W2957799212C2779951463 @default.
- W2957799212 hasConceptScore W2957799212C2780733359 @default.
- W2957799212 hasConceptScore W2957799212C2781025020 @default.
- W2957799212 hasConceptScore W2957799212C2984496839 @default.
- W2957799212 hasConceptScore W2957799212C71315377 @default.
- W2957799212 hasConceptScore W2957799212C71924100 @default.
- W2957799212 hasIssue "3" @default.
- W2957799212 hasLocation W29577992121 @default.
- W2957799212 hasLocation W29577992122 @default.
- W2957799212 hasLocation W29577992123 @default.
- W2957799212 hasLocation W29577992124 @default.
- W2957799212 hasOpenAccess W2957799212 @default.
- W2957799212 hasPrimaryLocation W29577992121 @default.
- W2957799212 hasRelatedWork W1992285201 @default.
- W2957799212 hasRelatedWork W2126451936 @default.
- W2957799212 hasRelatedWork W2226335814 @default.
- W2957799212 hasRelatedWork W2401976036 @default.
- W2957799212 hasRelatedWork W2941246023 @default.